Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.
Göteborg, Sweden. In J Psychiatry Neurosci, 17 Apr 2015
The levels of monocyte chemoattractant protein-1 (MCP-1), YKL-40, soluble cluster of differentiation 14 (sCD14), tissue inhibitor of metalloproteinases-1 (TIMP-1) and tissue inhibitor of metalloproteinases-2 (TIMP-2), were measured, and we adjusted comparisons between patients and controls for confounding factors.
Step-wise and punctuated genome evolution drive phenotype changes of tumor cells.
Ukraine. In Mutat Res, Jan 2015
To address the contribution of chromosome instability (CIN) to phenotype changes of tumor cells, we characterized CCAs/NCCAs of HeLa and HEK293 cells, and their derivatives after genotoxic stresses (a stable plasmid transfection, ectopic expression of cancer-associated CHI3L1 gene or treatment with temozolomide) by conventional cytogenetics, copy number alterations (CNAs) by array comparative genome hybridization, and phenotype changes by cell viability and soft agar assays.
Biomarkers of progression of chronic obstructive pulmonary disease (COPD).
Brisbane, Australia. In J Thorac Dis, Nov 2014
Examples of peripheral blood biological markers (biomarkers) include those associated with lung function (reduced CC-16), emphysema severity (increased adiponectin, reduced sRAGE), exacerbations and mortality [increased CRP, fibrinogen, leukocyte count, IL-6, IL-8, and tumor necrosis factor α (TNF-α)] including increased YKL-40 with mortality.
Biomarkers in connective tissue disease-associated interstitial lung disease.
Essen, Germany. In Semin Respir Crit Care Med, Apr 2014
Promising biomarkers are lung epithelium-derived proteins such as KL-6 (Krebs von den Lungen-6), SP-D (surfactant protein-D), SP-A (surfactant protein-A), YKL-40 (chitinase-3-like protein 1 [CHI3L1] or cytokines such as CCL18 [chemokine (C-C) motif ligand 18]).
Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.
New York City, United States. In Front Oncol, 2013
We review the current concept of developing YKL-40 as one of the most promising serum markers for glioblastoma, the recent advances on understanding the role of YKL-40 in gliomagenesis, and the promising evidence emerging from preclinical models on using this protein as a target for anti-glioma therapy.